The Killer Combo
A longer-lasting strategy to rejuvenate existing antibiotics with synergistic combinations is likely to play an integral role in the development of treatments against antibiotic resistant pathogens.
Anthony Coates | | Opinion
Bacteria are constantly evolving to be antibiotic resistant and are a real and present danger to our ability to treat common infections and carry out standard medical procedures, including organ transplantation, major surgery and cancer chemotherapy, among others. According to the O’Neill UK government AMR report (2016), global deaths from AMR may reach 10 million per year by 2050, which is more than cancer and diabetes combined (1).
Innovation in both the short and long term is essential if mankind is to keep pace with ever smarter and deadlier microbes. The fight to outsmart infection falls broadly into rapid diagnostics technology and targeted treatment strategies involving new and updated antibiotics.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- J O'Neill, ”Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance” (2016). Available at: https://bit.ly/2sGcZOz.
- WHO, “Antimicrobial resistance” (2018). Available at: https://bit.ly/2EdaHLq